Chronic Lower Back Pain
Stamford Therapeutics Consortium is currently conducting two studies on
chronic lower back pain.
Study #1 - Sponsored by Pfizer
Summary: The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.
Click here for more information
Study #2 - Sponsored by Zogenix, Inc.
Summary: The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.
Click here for more information
Website Designed And Maintained By Skye Communication, LLC.